PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
05-Apr-2022 New centre targets ‘undruggable’ cancers after major donation ICR
05-Apr-2022 DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy Vifor Pharma
05-Apr-2022 FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis Regeneron
05-Apr-2022 AI test could predict effective cancer drug combinations in less than two days ICR
05-Apr-2022 AstraZeneca Announces Results from ETESIAN Phase IIb trial AstraZeneca
05-Apr-2022 Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing safety and pharmacokinetics of second innovative formulation of 5-MeO-DMT Beckley Psytech
05-Apr-2022 In-person kick-off meeting of the Eurostars-funded REPRINT Asgard Therapeutics
05-Apr-2022 Aptamer’s leadership and technical achievements are recognised Aptamer
05-Apr-2022 CluePoints Continues Impressive Global Growth with Three New Senior Appointments CluePoints
05-Apr-2022 ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East ArisGlobal
05-Apr-2022 AXON hires a Global Healthcare Insights and Strategy Lead AXON
30-Mar-2022 Tower Cold Chain launches KTEvolution container for pharmaceutical transport Tower Cold Chain
30-Mar-2022 New analysis shows that Kesimpta®▼ (ofatumumab)-treated adults with relapsing remitting multiple sclerosis (RRMS) are not at increased risk of severe COVID-19 infections Novartis
29-Mar-2022 Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors AstraZeneca
29-Mar-2022 RECORDATI RARE DISEASES ANNOUNCE PUBLICATION IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM OF THE PHASE III LINC 4 STUDY CONFIRMING THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN PATIENTS WITH CUSHING’S DISEASE Recordati Rare Diseases
25-Mar-2022 ICR welcomes FDA approval of ‘search and destroy’ treatment The Institute of Cancer Research
25-Mar-2022 Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Tiziana Life Sciences Ltd
25-Mar-2022 XFret Wins the 2021 Sustainability Award – Startup/Small Business Category TIACA
25-Mar-2022 TIACA Announces the Take-Off of the BlueSky Program TIACA
25-Mar-2022 Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing Jazz Pharmaceuticals